B Cell Lymphoma
Clinical Insights
Efforts to close the ‘AYA gap’ in lymphoma
Feature
Seven things to know about new lymphoma drug tafasitamab
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Napabucasin suppressed tumor growth in DLBCL cell lines
Napabucasin suppressed tumor growth, decreased Ki67 and CD31 and increased cleaved caspase-3.
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
News
FDA approves new drug for diffuse large B-cell lymphoma
From the Journals
HSCT or systemic treatment should be offered to HIV+ patients with lymphoma
News
FDA approves selinexor for relapsed/refractory DLBCL
News from the FDA/CDC
FDA gives thumbs up to tazemetostat for follicular lymphoma
From the Journals
New EPOCH for adult patients with Burkitt lymphoma
From the Journals
American Cancer Society update: ‘It is best not to drink alcohol’